Latest for Arvinas

In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.

Arvinas’ lead protein degraders delivered promising early results in patients with hard-to-treat breast or prostate cancer.

Arvinas has released promising first-in-human data for its protein degrader in prostate cancer.

When it comes to tapping protein degraders to fight diseases like cancer, many assumed the biology worked, but the chemistry was no good. Arvinas...

Arvinas has inked another Big Pharma partnership to get their protein degradation engines revving — for both humans and crops.

PROTAC technology brings "unlimited" possibilities for cancer treatment says Arvinas founder & CSO Craig Crews. "It can be applied to so many...

Researchers at Arvinas are hijacking the cell’s protein-disposal system in the fight against Alzheimer’s and intractable cancers.

Arvinas, a preclinical biotech developing protein degradation therapies for advanced cancers, raised $120 million by offering 7.5 million shares at...